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Abstract
Transcriptional and post-transcriptional regulation shape tissue-type-specific proteomes, but their
relative contributions remain contested. Estimates of the factors determining protein levels in hu-
man tissues do not distinguish between (i) the factors determining the variability between the abun-
dances of different proteins, i.e., mean-level-variability and, (ii) the factors determining the physi-
ological variability of the same protein across different tissue types, i.e., across-tissues variability.
We sought to estimate the contribution of transcript levels to these two orthogonal sources of vari-
ability, and found that scaled mRNA levels can account for most of the mean-level-variability but
not necessarily for across-tissues variability. The reliable quantification of the latter estimate is
limited by substantial measurement noise. However, protein-to-mRNA ratios exhibit substantial
across-tissues variability that is functionally concerted and reproducible across different datasets,
suggesting extensive post-transcriptional regulation. These results caution against estimating pro-
tein fold-changes from mRNA fold-changes between different cell-types, and highlight the contri-
bution of post-transcriptional regulation to shaping tissue-type-specific proteomes.
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2Author Summary
The identity of human tissues depends on their protein levels. Are tissue protein levels set largely
by corresponding mRNA levels or by other (post-transcriptional) regulatory mechanisms? We
revisit this question based on statistical analysis of mRNA and protein levels measured across
human tissues. We find that for any one gene, its protein levels across tissues are poorly predicted
by its mRNA levels, suggesting tissue-specific post-transcriptional regulation. In contrast, the
overall protein levels are well predicted by scaled mRNA levels. We show how these speciously
contradictory findings are consistent with each other and represent the two sides of Simpson’s
paradox.
Introduction
The relative ease of measuring mRNA levels has facilitated numerous investigations of how cells
regulate their gene expression across different pathological and physiological conditions [1–6].
However, often the relevant biological processes depend on protein levels, and mRNA levels are
merely proxies for protein levels [7]. If a gene is regulated mostly transcriptionally, its mRNA level
is a good proxy for its protein level. Conversely, post-transcriptional regulation can set protein
levels independently from mRNA levels, as in the cases of classical regulators of development [8],
cell division [9, 10] and metabolism [11, 12]. Thus understanding the relative contributions of
transcriptional and post-transcriptional regulation is essential for understanding their trade-offs
and the principles of biological regulation, as well as for assessing the feasibility of using mRNA
levels as proxies for protein levels.
Previous studies have considered single cell-types and conditions in studying variation in ab-
solute mRNA and protein levels genome-wide, often employing unicellular model organisms or
mammalian cell cultures [13–19]. However, analyzing per-gene variation in relative mRNA and
protein expression across different tissue types in a multicellular organism presents a potentially
different and critical problem which cannot be properly addressed by examining only genome-
scale correlations between mRNA and protein levels. [20–22] have measured protein levels across
human tissues, thus providing valuable datasets for analyzing the regulatory layers shaping tissue-
3type-specific proteomes. The absolute levels of proteins and mRNAs in these datasets correlate
well, highlighting that highly abundant proteins have highly abundant mRNAs. Such correlations
between the absolute levels of mRNA and protein mix/conflate many sources of variation, includ-
ing variability between the levels of different proteins, variability within the same protein across
different conditions and cell-types, and the variability due to measurement error and technological
bias.
However, these different sources of variability have very different biological interpretations
and implications. A major source of variability in protein and mRNA data arises from differences
between the levels of mRNAs and proteins corresponding to different genes. That is, the mean
levels (averaged across tissue-types) of different proteins and mRNAs vary widely. We refer to
this source of variability as mean-level variability. This mean-level variability reflects the fact
that some proteins, such as ribosomal proteins, are highly abundant across all profiled tissues
while other proteins, such as cell cycle and signaling regulators, are orders of magnitude less
abundant across all profiled conditions [20]. Another principal source of variability in protein
levels, intuitively orthogonal to the mean-level variability, is the variability within a protein across
different cell-types or physiological conditions and we refer to it as across-tissues variability.
The across-tissues variability is usually much smaller in magnitude, but may be the most relevant
source of variability for understanding different phenotypes across cells-types and physiological
conditions.
Here, we sought to separately quantify the contributions of transcriptional and post-transcriptional
regulation to the mean-level variability and to the across-tissues variability across human tissues.
Our results show that the much of the mean-level protein variability can be explained well by
mRNA levels while across-tissues protein variability is poorly explained by mRNA levels; much of
the unexplained variance is due to measurement noise but some of it is reproducible across datasets
and thus likely reflects post-transcriptional regulation. These results add to previous results in the
literature [13–18, 20, 22] and suggest that the post-transcriptional regulation is a significant con-
tributor to shaping tissue-type specific proteomes in human.
4Results
The correlation between absolute mRNA and protein levels conflates distinct
sources of variability
We start by outlining the statistical concepts underpinning the common correlational analysis and
depiction [13, 15, 17, 20] of estimated absolute protein and mRNA levels as displayed in Fig 1a,b.
The correlation between the absolute mRNA and protein levels of different genes and across differ-
ent tissue-types has been used to estimate the level at which the protein levels are regulated [20,22].
One measure reflecting the post-transcriptional regulation of a gene is its protein to mRNA
ratio, which is sometimes referred to as a gene’s “translational efficiency”. Since this ratio also
reflects other layers of regulation, such as protein degradation and noise [18], we will refer to it de-
scriptively as protein-to-mRNA (PTR) ratio. If the across-tissues variability of a gene is dominated
by transcriptional regulation, its PTR in different tissue-types will be a gene-specific constant.
Based on this idea, [20, 22] estimated these protein-to-mRNA ratios and suggested that the me-
dian PTR for each gene can be used to scale its tissue-specific mRNA levels and that this “scaled
mRNA” predicts accurately tissue-specific protein levels.
Indeed, mRNA levels scaled by the corresponding median PTR explain large fraction of the
total protein variance (R2T = 0.70, across all measured proteins, Fig 1a,b) as previously observed
[15, 20, 22]. However, this high R2T does not indicate concordance for across-tissues variability of
mRNAs and proteins. R2T quantifies the fraction of the total protein variance explained by mRNA
levels between genes and across tissue-types; thus, it conflates the mean-level variability with the
across-tissues variability. This conflation is shown schematically in Fig 1c for a subset of 100 genes
measured across 12 tissues. The across-tissues variability is captured by the variability within the
regression fits while the mean-level variability is captured by the variability between the regression
fits.
Such aggregation of distinct sources of variability, where different subgroups of the data show
different trends, may lead to counter-intuitive results and incorrect conclusions, and is known as the
Simpson’s or amalgamation paradox [23]. To illustrate the Simpson’s paradox in this context, we
depicted a subset of genes for which the measured mRNA and protein levels are unrelated across-
tissues while the mean-level variability still spans the full dynamic range of the data, Fig 1c. For
5this subset of genes, the overall (conflated/amalgamated) correlation is large and positive, despite
the fact that all across-tissues (within-gene) trends are close to zero. This counter-intuitive result
is possible because the conflated correlation is dominated by the variability with larger dynami-
cal range, in this case the mean-level variability. This conceptual example using data from [20]
demonstrates that R2T is not necessarily informative about the across-tissues variability, i.e., the
protein variance explained by scaled mRNA within a gene (R2P ). Thus the conflated correlation
is not generally informative about the level — transcriptional or post-transcriptional — at which
across-tissues variability is regulated. This point is also illustrated in Fig S1 with data for all
quantified genes: The correlations between scaled mRNA and measured protein levels are not in-
formative for the correlations between the corresponding relative changes in protein and mRNA
levels.
To further illustrate this point with more datasets, Fig 1d displays the cumulative distributions
of across-tissues mRNA-protein correlations (RP) for all proteins quantified across the large shot-
gun datasets [20, 21], as well as the corresponding conflated correlations between scaled mRNA
and protein levels (RT). This depiction demonstrates that RT are not representative for RP. To
extended this analysis to protein levels measured by targeted MS [22], we plotted the distributions
of across-tissues mRNA-protein correlations (RP) for the subset of 33 genes quantified across all
datasets [20–22]; see dotted curves in Fig 1d. These genes were selected to have larger variance
across tissues [22] and have relatively higher across-tissues correlations, especially in the data
by [21, 22]. Nevertheless, all datasets include low and even negative across-tissues correlations
(RP) and very high conflated correlations between scaled mRNA and protein levels (RT), Fig 1d.
These results underscore the weak connection between RP and RT even for a carefully selected and
measured subset of mRNAs and proteins.
The across-tissues variability has a dynamic range of about 2− 10 fold and is thus dwarfed by
the 103 − 104 fold dynamic range of abundances across different proteins. While across-tissues
variability is smaller than mean-level variability, it is exactly the across-tissues variability that
contributes to the biological identity of each tissue type and we focus the rest of our analysis to
factors regulating the across-tissues protein variability.
6Estimates of transcriptional and post-transcriptional regulation across-tissues
depend strongly on data reliability
Next, we sought to estimate the fractions of across-tissues protein variability due to transcriptional
regulation and to post-transcriptional regulation. This estimate depends crucially on noise in the
mRNA and protein data, from sample collection to measurement error. Both RNA-seq [24, 25]
and mass-spectrometry [15, 26] have relatively large and systematic error in estimating absolute
levels of mRNAs and proteins, i.e., the ratios between different proteins/mRNAs. These errors
originate from DNA sequencing GC-biases, and variations in protein digestion and peptide ioniza-
tion. However, relative quantification of the same gene across tissue-types by both methods can be
much more accurate since systematic biases are minimized when taking ratios between the inten-
sities/counts of the same peptide/DNA-sequence measured in different tissue types [18,25,27,28].
It is this relative quantification that is used in estimating across-tissues variability, and we start by
estimating the reliability of the relative quantification across human tissues, Fig 2a-d. Reliabil-
ity is defined as the fraction of the observed/empirical variance due to signal. Thus reliability is
proportional to the signal strength and decreases with the noise levels.
To estimate the within study reliability of mRNA levels, we took advantage that each mRNA
dataset contains data from multiple subjects. We split the subjects in each dataset into two sub-
sets, each of which containing measurements for all 12 tissues from several subjects. The levels
of each mRNA were estimated from each subset by averaging across subjects and the estimates
from the two subsets correlated, Fig 2a. These correlations provide estimates for the reliability
of each mRNA and their median provides a global estimate for the reliability of relative RNA
measurement, not taking into account noise due to sample collection and processing.
To estimate the within study reliability of protein levels, we computed separate estimates of the
relative protein levels within a dataset. For each protein, Estimate 1 was derived from 50 % of the
quantified peptides and Estimate 2 from the other 50 %. Since much of the analytical noise related
to protein digestion, chromatographic mobility and peptide ionization is peptide-specific, such
non-overlapping sets of of peptides provide mostly, albeit not completely, independent estimates
for the relative protein levels. The correlations between the estimates for each protein (averaging
across 12 tissues) are displayed as a distribution in Fig 2b.
7In addition to the within study measurement error, protein and mRNA estimates can be affected
by study-dependable variables such as sample collection and data processing. To account for
these factors, we estimated across study reliability by comparing estimates for relative protein and
mRNA levels derived from independent studies, Fig 2c-d. For each gene, we estimate the reliability
for each protein by computing the the empirical correlation between mRNA abundance reported
by the ENCODE [29] and by [30]. The correlations in Fig 2c have much broader distribution
than the within-study correlations, indicating that much of the noise in mRNA estimates is study-
dependent.
To estimate the across study reliability of protein levels, we compared the protein levels es-
timated from data published by [20] and [21]. To quantify protein abundances, [20] used iBAQ
scores and [21] used spectral counts. To ensure uniform processing of the two datasets, we down-
loaded the raw data and analyzed them with maxquant using identical settings, and estimated
protein abundances in each dataset using iBAQ; see Methods. The corresponding estimates for
each protein were correlated to estimate their reliability. Again, the correlations depicted in Fig
2d have a much broader distribution compared to the within-study protein correlations in Fig 2b,
indicating that, as with mRNA, the vast majority of the noise is study-dependent. As a representa-
tive estimate of the reliability of protein levels, we use the median of the across tissue correlations
from Figures 2c-d.
The across tissues correlations and the reliability of the measurements can be used to esti-
mate the across tissues variability in protein levels that can be explained by mRNA levels (i.e.,
transcriptional regulation) as shown in Fig 2e; see Methods. As the reliabilities of the protein
and the mRNA estimates decrease, the noise sensitivity of the estimated transcriptional contri-
bution increases. Although the average across-tissues mRNA protein correlation was only 0.29
(R2 = 0.08), the data are consistent with approximately 50% of the variance being explained by
transcriptional regulation and approximately 50% coming from post-transcriptional regulation; see
Fig S2 for reliability-corrected estimates for specific functional gene sets. However, the low relia-
bility of the data and large sampling variability precludes making such estimate reliable. Thus, we
next considered analyses that can provide estimates for the scope of post-transcriptional regulation
even when the reliability of the data is low.
8Coordinated post-transcriptional regulation of functional gene sets
The low reliability of estimates across datasets limits the reliability of estimates of transcriptional
and post-transcriptional regulation for individual proteins, Fig 2. Thus, we focused on estimating
the post-transcriptional regulation for sets of functionally related genes as defined by the gene
ontology (GO) [31]. By considering such gene sets, we may be able to average out some of
the measurement noise and see regulatory trends shared by functionally related genes. Indeed,
some of the noise contributing to the across-tissues variability of a gene is likely independent
from the function of the gene; see Methods. Conversely, genes with similar functions are likely
to be regulated similarly and thus have similar tissue-type-specific PTR ratios. Thus, we explored
whether the across-tissues variability of the PTR ratios of functionally related genes reflects such
tissue-type-specific and biological-function-specific post-transcriptional regulation.
Since this analysis aims to quantify across-tissues variability, we define the “relative protein
to mRNA ratio” (rPTR) of a gene in a given tissue to be the PTR ratio in that tissue divided by
the median PTR ratio of the gene across the other 11 tissues. We evaluated the significance of
rPTR variability for a gene-set in each tissue-type by comparing the corresponding gene-set rPTR
distribution to the rPTR distribution for those same genes pooled across the other tissues (Fig 3);
we use the KS-test to quantify the statistical significance of differences in the rPTR distributions;
see Methods. The results indicate that the genes from many GO terms have substantially higher
rPTR in some tissues than in others. For example the ribosomal proteins of the small subunit (40S)
have high rPTR in kidney but low rPTR in stomach (Fig 3a-c).
While the strong functional enrichment of rPTR suggests functionally concerted post-transcriptional
regulation, it can also reflect systematic dataset-specific measurement artifacts. To investigate this
possibility, we obtained two estimates for rPTR from independent datasets: Estimate 1 is based on
data from [20] and [30], and Estimate 2 is based on data from [21] and [29]. These two estimates
are reproducible (e.g., ρ = 0.7 − 0.8) for most tissues but less for others (e.g., ρ = 0.14), as
shown by the scatter plots between the median rPTR for GO terms in Fig 3d; Fig S3 shows the
reproducibility for all tissues. The correlations between the two rPTR estimates remain statisti-
cally significant albeit weaker (i.e., ρ = 0.1 − 0.4) when computed with all GO terms (not only
those showing significant enrichment) as shown in Table S1, as well as when computed between
the rPTRs for all genes, Table S2.
9Consensus protein levels
Given the low reliability of protein estimates across studies Fig 2, we sought to increase it by
deriving consensus estimates. Indeed, by appropriately combining data from both protein studies,
we can average out some of the noise thus improving the reliability of the consensus estimates; see
Methods. As expected for protein estimates with increased reliability, the consensus protein levels
correlate better to mRNA levels than the corresponding protein levels estimated from a either
dataset alone, Fig 4a,b. We further validate our consensus estimates against 124 protein/tissue
measurements from a targeted MS study by [22]. We computed the mean squared errors (MSE)
between the protein levels estimated from the targeted study and the other three datasets using
only protein/tissue measurements quantified in all datasets, facilitating fair comparison (Fig 4c).
The MSE are lower for the consensus dataset than for either [20] or [21] and are consistent with a
10% error reduction relative to the [21] dataset. In addition to increased reliability, the consensus
dataset increased coverage, providing a more comprehensive quantification of protein levels across
human tissues than either draft of the human proteome taken alone (Table 1).
Discussion
Highly abundant proteins have highly abundant mRNAs. This dependence is consistently observed
[13–15, 17, 18] and dominates the explained variance in the estimates of absolute protein levels
(Fig 1 and Fig S1). This underscores the role of transcription for setting the full dynamic range of
protein levels. In stark contrast, differences in the proteomes of distinct human tissues are poorly
explained by transcriptional regulation, Fig 1. This is due to measurement noise (Fig 2) but also
to post-transcriptional regulation. Indeed, large and partially reproducible rPTR ratios suggest that
the mechanisms shaping tissue-specific proteomes involve post-transcriptional regulation, Fig 3.
This result underscores the role of translational regulation and of protein degradation for mediating
physiological functions within the range of protein levels consistent with life.
As with all analysis of empirical data, the results depend on the quality of the data and the
estimates of their reliability. This dependence on data quality is particularly strong given that
some conclusions rest on the failure of across-tissues mRNA variability to predict across-tissues
protein variability. Such inference based on unaccounted for variability is substantially weaker than
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measuring directly and accounting for all sources of variability. The low across study reliability
suggest that the signal is strongly contaminated by noise, especially systematic biases in sample
collection and handling, and thus the data cannot accurately quantify the contributions of different
regulatory mechanisms, Fig 2. Another limitation of the data is that isoforms of mRNAs and
proteins are merged together, i.e., using razor proteins. This latter limitation is common to all
approaches quantifying proteins and mRNAs from peptides/short-sequence reads. It stems from
the limitation of existing approaches to infer and distinctly quantify isoforms and proteoforms.
The strong enrichment of rPTR ratios within gene sets (Fig 3) demonstrates a functionally
concerted regulation at the post-transcriptional level. Some of the rPTR trends can account for
fundamental physiological differences between tissue types. For example, the kidney is the most
metabolically active (energy consuming) tissue among the 12 profiled tissues [32] and it has
very high rPTR for many gene sets involved in energy production (Fig 3a). In this case, post-
transcriptional regulation likely plays a functional role in meeting the high energy demands of
kidneys. Quantifying and understanding mRNA and protein covariation in single cells is an im-
portant frontier of this analysis [33].
The rPTR patterns and the across tissue correlations in Fig S1 indicate that the relative con-
tributions of transcriptional and post-transcriptional regulation can vary substantially depending
on the tissues compared. Thus, the level of gene regulation depends strongly on the context. For
example transcriptional regulation is contributing significantly to the dynamical responses of den-
dritic cells [18] and to the differences between kidney and prostate gland (Fig S1h) but less to the
differences between kidney and liver (Fig S1g). All data, across all profiled tissues, suggest that
post-transcriptional regulation contributes substantially to the across-tissues variability of protein
levels. The degree of this contribution depends on the context.
Indeed, if we only increase the levels for a set of mRNAs without any other changes, the cor-
responding protein levels must increase proportionally as demonstrated by gene inductions [34].
However, the differences across cell-types are not confined only to different mRNA levels. Rather,
these differences include different RNA-binding proteins, alternative untranslated regions (UTRs)
with known regulatory roles in protein synthesis, specialized ribosomes [35–38], and different
protein degradation rates [39–43]. The more substantial these differences, the bigger the potential
for post-transcriptional regulation. Thus cell-type differentiation and commitment may result in
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much more post-transcriptional regulation than observed during perturbations preserving the cel-
lular identity. Consistent with this possibility, tissue-type specific proteomes may be shaped by
substantial post-transcriptional regulation; in contrast, cell stimulation that preserves the cell-type,
may elicit a strong transcriptional remodeling but weaker post-transcriptional remodeling.
Methods
Data sources
We used RNA estimates based on RNA-seq from [29, 30] and protein estimates based on shotgun
mass-spectrometry from [20, 21]. These large scale datasets contained N = 6104 genes measured
in each of twelve different human tissues: adrenal gland, esophagus, kidney, ovary, pancreas,
prostate, salivary gland, spleen, stomach, testis, thyroid gland, and uterus. For these genes, about
8% of the mRNA measurements and about 40% of the protein measurements are missing. The
mRNA datasets contain measurements from multiple subjects/people and the subjects were split
into two subsets in estimating the within study reliability in Fig 2a. We also used a small scale
targeted dataset from [22] containing data for 33 proteins measured across 5 tissues. The datasets
were collected by different groups and measurements derived from different subjects.
Searching raw MS data
Raw data from [21, 22] were searched by MaxQuant [44] 1.5.7.0 against a protein sequence
database including all entries from a Human UniProt database from 2015 and known contaminants
such as human keratins and common laboratory contaminants. MaxQuant searches were per-
formed with trypsin specificity allowing up to two missed cleavages, with fixed Carbamidomethyl
acetylation on cysteines, and with variable modifications allowing methionine oxidation and acety-
lation on Protein N-termminus. All razor peptides were used for quantifying the proteins to which
they were assigned by MaxQuant. False discovery rate (FDR) was set to 1% at both the protein
and the peptide levels.
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Scaling mRNA levels
First, denote mit the log mRNA levels for gene i in tissue t. Similarly, let pit denote the corre-
sponding log protein levels. First, we normalize the columns of the data, for both protein and
mRNA, to different amounts of total protein per sample. Any multiplicative factors on the raw
scale correspond to additive constants on the log scale. Consequently, we normalize data from
each tissue-type by minimizing the absolute differences between data from the tissue and the first
tissue (arbitrarily chosen as a baseline). That is, for all t > 1, we define
pnit = (p
u
it − µˆt)
with
µˆt = argmin
µ
∑
i
|pui1 − (puit − µ)|
Where pnit and p
u
it represent the normalized and non-normalized protein measurements respectively.
For each t, the value of µt which minimizes the absolute difference is
µˆt = median
u
(pi1 − puit)
We use the same normalization for mRNA. This normalization, which corresponds to a location
shift of the log abundances for each tissue, corrects for any multiplicative differences in the raw
(unlogged) mRNA or protein. We normalize these measurements by aligning the medians rather
than the means, as the median is more robust to outliers.
After normalization, we define rit = pit −mit as the log PTR ratio of gene i in condition t. If
the post-transcriptional regulation for the ith gene were not tissue-specific, then the ith PTR ratio
would be independent of tissue-type and can be estimated as
Tˆi = median
t
(pit −mit)
In such a situation the log “scaled mRNA” (or mean protein level) can be defined as
pit = mit + Ti
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On the raw scale this amounts to scaling each mRNA by its median PTR ratio and represents and
estimate of the mean protein level. The residual difference between the log mean protein level and
the measured log protein level, which we call the log rPTR ratio
rit = pit − pit
consists of both tissue-specific post-transcriptional regulation and measurement noise.
Across-tissues correlations
For each gene, i, we compute the correlation between mRNA and protein across tissues. Unlike
the between gene correlations which are consistently large after scaling for each tissue (Figure
1a), across-tissues correlations are highly variable between genes. Although this could be in part
because true mRNA/protein correlations vary significantly between genes, a huge amount of the
heterogeneity can be explained by sampling variability. There are only 10 and 12 tissues in com-
mon across datasets (depending on which datasets are used) and for many genes the abundances
are missing, which means that the empirical estimates of across tissue correlation for each gene
are very noisy. To find a representative estimate of the across-tissues correlation we can take the
median over all genes. As an alternative, if the correlation was roughly constant between genes,
we could pool information to yield a representative estimate of this across-tissues correlation. For
a gene i, we compute the Fisher transformation of the within-gene correlation. This Fisher trans-
formation, zi = arctanh(rˆi) is approximately normally distributed:
zi ∼ N
(
1
2
log(
1 + ρ
1− ρ),
1√
Ni − 3
)
where Ni are the number of observed mRNA-protein pairs for gene i (at most 11) and ρ corre-
sponds to the population correlation. We estimate the maximum likelihood estimate of the Fisher
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transformed population correlation by weighting each observation by its variance:
ωi =
1
ni − 3
Wi =
ωi∑
j ωj
zˆpop =
∑
Wizi
We then transform this estimate back to the correlation scale
ρˆ =
e2zˆpop − 1
e2zˆpop + 1
Depending on the data sets used, with this method we estimate the population across-tissues
mRNA/protein correlation to be between 0.21 ( [20]) and 0.29 ( [21]). This correlation cannot be
used as direct evidence for the relationship between mRNA and protein levels since both mRNA
and protein datasets are unreliable due to measurement noise. This measurement noise attenuates
the true correlation. Below we address this by directly estimating data reliability and correcting
for noise.
Noise correction
Measurement noise attenuates estimates of correlations between mRNA and protein level [45]. A
simple way to quantify this attenuation of correlation due to measurement error is via Spearman’s
correction. Spearman’s correction is based on the fact that the variance of the measured data can
be decomposed into the sum of variance of the noise and the signal. If the noise and the signal are
independent, this decomposition and the Spearman’s correction are exact [17].
Note that it is simple to show that the empirical variance is the sum of the variance of the signal
and the variance of the noise:
• ei - Expectation at the ith data point; e˜i = ei − 〈e〉
• ζi - Noise at the ith data point; 〈ζ〉 = 0
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• xi - Observation at the ith data point; x˜i = xi − 〈x〉, xi = ei + ζi;
σ2x =
1
n
∑
i
x˜2i =
1
n
∑
i
(e˜i + ζi)
2 =
=
1
n
∑
i
e˜2i︸ ︷︷ ︸
σ2e
+
1
n
∑
i
ζ2i︸ ︷︷ ︸
σ2ζ
+
2
n
∑
i
e˜iζi︸ ︷︷ ︸
≈0
Spearman’s correction is based on estimates of the “reliability” of the measurements, which is
defined as the fraction of total measured variance due to signal rather than to noise:
Reliability =
σ2signal
σ2total
(1)
= 1− σ
2
err
σ2err + σ
2
signal
(2)
If X and Y are noisy measurements of two quantities, we can compute the noise corrected corre-
lation between them as
Cor(X, Y )√
Rel(X)Rel(Y )
(3)
(4)
In practice, reliabilities are not known but we can often estimate them. In this application, for
both mRNA and protein we need measurements in which all steps, from sample collection to
level estimation, are repeated independently. In order to estimate the mRNA reliabilities we use
independent measurements from [30] and [29]. For estimating protein reliabilities we use mea-
surements from [20] and [21]. across-tissues reliabilities are computed per gene whereas within-
tissue reliabilities are computed per tissue across genes. If two independent measurements have
the same reliability, it can be estimated by computing the correlation between the two measure-
ments [17, 46, 47]. We estimated the approximate across-tissues protein reliability to be 0.21 and
the across-tissues mRNA reliability to be 0.77. Given the estimated across-tissues mRNA/protein
correlation of 0.29 (calculated using data from [21] and [30]) we estimated the noise-corrected
fraction of across-tissues protein variance explained by mRNA to be approximately 50%, Figure
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2. Note that if both mRNA or both protein datasets share biases, then the estimated reliabilities will
be too small, thus deflating the inferred fraction of protein variance explained by mRNA. More-
over, because the reliabilities are low, sampling variability is large, missing data is prevalent, and
mRNA/protein correlation likely vary by gene there is uncertainty about this estimate.
Creating a consensus protein dataset
We use the two independent protein datasets to create a single consensus data set which is of ar-
guably higher reliability than either dataset individually. To create this dataset, we take a weighted
average of the two protein abundance datasets, by tissue. We compute the weights based on mea-
surement reliabilities for each tissue in each of the two datasets.
Assume we have two random variables,
∼
X1 and
∼
X2, corresponding to measurements on the
same quantity (e.g. two independent protein measurements) with
∼
X i = X + i where X ∼
N(0, σ2X) is the signal which is independent of i ∼ N(0, σ2i), the measurement error for sample
i. We have a third random variable corresponding to a different quantity (e.g. an mRNA measure-
ment),
∼
Y that is typically positively correlated with
∼
X1 and
∼
X2 with the same covariance σ2XY . To
create the consensus data set we first compute the reliability of
∼
X i Rel(
∼
X i) =
σ2X
σ2∼
Xi
=
σ2X
σ2X+σ
2
i
for
both datasets.
Note that
Cor(
∼
X1,
∼
X2) =
σ2X
σ∼
X1
σ∼
X2
Cor(
∼
X i, Y ) =
σ2XY
σ∼
Xi
σY
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Thus,
Cor(
∼
X1,
∼
X2)
Cor(
∼
X1,
∼
Y )
Cor(
∼
X2,
∼
Y )
=
σ2X
σ2∼
X1
=
σ2X
σ2X + σ
2
1
= Rel(
∼
X1)
Similarly, Cor(
∼
X1,
∼
X2)
Cor(
∼
X2,
∼
Y )
Cor(
∼
X1,
∼
Y )
= Rel(
∼
X2). We use these facts and compute the empirical corre-
lations between datasets to independently estimate the across gene reliabilities for each tissue from
each dataset. We then Fisher weight the protein abundances based on their reliabilities. That is,
for each tissue t, the consensus dataset, XCt is
XCt = w
∼
X
t
t + (1− w)
∼
X
2
t
w =
Rel(
∼
X
1
t )
Rel(
∼
X
1
t ) +Rel(
∼
X
2
t )
When the reliability of
∼
X
1
t and
∼
X
2
t are close, each dataset is weighted equally. When one reliability
dominates the other, that dataset contributes more to the aggregated dataset. We found that the full
consensus data set has a higher median per gene correlation with mRNA than either of the protein
datasets individually (0.34) and agreed more closely with validation data from [22] (Table 1).
Functional gene set analysis
To identify tissue-specific rPTR for functional sets of genes, we analyzed the distributions of rPTR
ratios within functional gene-sets using the same methodology as [48]. We restrict our attention to
functional groups in the GO ontology [31] for which at least 10 genes were quantified by [20]. Let
k index one of these approximately 1600 functional gene sets. First, for every gene in every tissue
we estimate the relative PTR (rPTR) or equivalently, the difference between log mean protein level
and measured protein level:
rˆit = pit −median
t′ 6=t
(pit′ −mit′)
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To exclude the possibility that rˆit = 0 exactly, we require that t′ 6= t. When the estimated
rPTR is larger than zero, the measured protein level in tissue t is larger than the estimated mean
protein level. Likewise, when this quantity is smaller than zero, the measured protein is smaller
than expected. Measured deviations from the mean protein level are due to both measurement
noise and tissue specific PTR. To eliminate the possibility that all of the variability in the rPTR
ratios is due to measurement error we conduct a full gene set analysis.
For each of the gene sets we compute a vector of these estimated log ratios so that a gene set is
comprised of
Gkt = {rˆi1j, ..., rˆink t}
where i1 to ink index the genes in set k and t indexes the tissue type.
Let KS(G1,G2) be the function that returns the p-value of the Kolmogorov-Smirnov test on
the distribution in sets G1 and G2. The KS-test is a test for a difference in distribution between two
samples. Using this test, we identify gene sets that show systematic differences in PTR ratio in a
particular tissue (t) relative to all other tissues.
Specifically, the p-value associated with gene set k in condition j is
ρkt = KS(Gkt, ∪
t′ 6=t
Gkt′)
To correct for testing multiple hypotheses, we computed the false discovery rate (FDR) for all
gene sets in tissue t [49]. In Figure 3a-c, we present only the functional groups with FDR less
than 1% and report their associated p-values. Note that the test statistics for each gene set are pos-
itively correlated since the gene sets are not disjoint, but [50] prove that the Benjamini-Hochberg
procedure applied to positively correlated test statistics is conservative. Thus, the significance of
of certain functional groups suggests that not all of the variability in rPTR is due to measurement
noise. We also calculated rPTR using two pairs of measurements: one set of rPTR estimates was
calculated using protein data from [20] and mRNA from [30] and the other was calculated using
data from [21] and [29]. rPTR of the significant sets was largely reproducible across estimates
from independent datasets (Figure 3d) and less reproducible across genes (Table S2). Note that
when computing the per tissue reliabilities for the construction of the consensus data set, we found
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that the reliabilities of the lung and pancreas datasets from [20] were much less reliable than the
data from [21]. This could explain why the independent estimates of the rPTR ratios for these
tissues were less reproducible.
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Tables
Wilhelm et al. Kim et al. Consensus
Tissue type Proteins Peptides Proteins Kim pep Proteins Peptides
Adrenal Gland 3,947 43,661 3,610 40,619 4,436 62,719
Colon 3,745 34,925 4,004 32,786 4,517 52,872
Esophagus 3,989 39,677 1,682 15,298 4,086 45,881
Kidney 3,045 34,740 2,814 26,499 3,526 45,865
Liver 3,669 34,844 2,307 22,992 3,971 45,168
Lung 2,852 31,293 2,935 29,686 3,704 47,617
Ovary 3,681 41,289 3,568 53,956 4,419 72,337
Pancreas 3,048 30,463 2,326 19,974 3,423 38,807
Prostate 3,467 38,562 3,118 33,765 3,932 51,891
Testis 3,950 51,369 3,505 42,865 4,478 70,952
Spleen 3,244 39,465 0 0 3,237 39,465
Stomach 3,957 44,609 0 0 3,949 44,609
Heart 3,957 0 2,227 27,205 2,227 27,205
All 5,719 113,069 5,326 105,158 5,786 150,830
Table 1. Proteome coverage. Number of quantified proteins and peptides in 3
datasets: [20], [21], and the consensus dataset derived here. The consensus data have the highest
coverage and the best agreement with the validation dataset, Fig 4.
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Figure 1. The fraction of total protein variance explained by scaled mRNA levels is not
informative about the across-tissues variance explained by scaled mRNA levels. (a) mRNA
levels correlate with measured protein levels (RT = 0.33 over all measured mRNAs and proteins
across 12 different tissues). (b) Protein levels versus mRNA levels scaled by the median
protein-to-mRNA ratio (PTR); the only change from panel (a) is the scaling of mRNAs which
considerably improves the correlation. (c) A subset of 100 genes are used to illustrate an example
Simpson’s paradox: regression lines reflect within-gene and across-tissues variability. Despite the
fact that the overall correlation between scaled mRNA and measured protein levels is large and
positive RT = 0.89, for any single gene in this set, mRNA levels scaled by the median PTR ratio
are not correlated to the corresponding measured protein levels (RP ≈ 0). (d) Cumulative
distributions of across-tissues scaled mRNA-protein correlations (RP) for 3 datasets [20–22]. The
smooth curves correspond to all quantified proteins by shotgun proteomics while the dashed
curves correspond to a subset of proteins quantified in a small targeted dataset [22]. The vertical
lines show the corresponding overall (conflated) correlation between scaled mRNA levels and
protein levels, RT. See Methods and Fig S1.
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Figure 2. Data reliability crucially influences estimates of transcriptional and
post-transcriptional regulation across-tissues. (a) The within-study reliability – defined as the
fraction of the measured variance due to the signal – of relative mRNA levels is estimated as the
correlation between the mRNA levels measured in the twelve different tissues. Estimates for the
levels of each transcript measured in different subjects were correlated (averaging across the 12
tissue-types) and the results for all analyzed transcripts displayed as a distribution for each RNA
dataset [29, 30]. (b) The within-study reliability of relative protein levels is estimated as the
correlation between the protein levels measured in 12 different tissues [20, 21]. Within each
dataset, separate estimates for each protein were derived from non-overlapping sets of peptides
and were correlated (averaging across the 12 tissue-types) and the results for all analyzed proteins
displayed as a distribution; see Methods. (c) The across-study reliability of mRNA was estimated
by correlating estimates as in (a) but these estimates came from different studies [29] and [30].
(d) The across-study reliability of proteins was estimated by correlating estimates as in (b) but
these estimates came from different studies [20] and [21]. (e) The fraction of across-tissues
protein variance that can be explained by mRNA levels is plotted as a function of the reliability of
the estimates of mRNA and protein levels, given an empirical mRNA/protein correlation of 0.29.
The red Xs correspond to two estimates of reliability of the mRNA and protein measurements
computed from both independent mRNA and protein datasets.
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Figure 3. Concerted variability in the relative protein-to-RNA (rPTR) ratio of functional
gene-sets across tissue-types (a) mRNAs coding for the ribosomal proteins, NADH
dehydrogenase and respiratory proteins have higher protein-to-mRNA ratios in kidney as
compared to the median across the other 11 tissues (FDR < 1%). In contrast mRNAs genes
functioning in Rac GTPase binding have lower protein-to-mRNA ratios (FDR < 1%). (b) The
stomach also shows significant rPTR variation, with low rPTR for the ribosomal proteins and
high rPTR for tRNA-aminoacylation (FDR < 1%). (c) Summary of rPTR variability, as depicted
in panel (a-b), across all tissues and many gene ontology (GO) terms. Metabolic pathways and
functional gene-sets that show statistically significant (FDR < 1%) variability in the relative
protein-to-mRNA ratios across the 12 tissue types. All data are displayed on a log10 scale, and
functionally related gene-sets are marked with the same color. (d) The reproducibility of rPTR
estimates across estimates from different studies is estimated as the correlation between the
median rPTRs for GO terms showing significant enrichment as shown in panels (a-c). See
Methods, Fig S2 and Fig S3.
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Mean Squared Error
Tissue Wilhelm et al. Kim et al. Consensus
Prostate 0.45 0.35 0.35
Lung 0.58 0.22 0.18
Liver 0.81 0.16 0.16
Colon 0.39 0.32 0.28
Kidney 0.53 0.66 0.53
All 0.54 0.37 0.32
Figure 4. Deriving a consensus protein dataset for improved quantification of human tissue
proteomes We compiled a consensus protein dataset by merging data from [20] and [21] as
described in Methods. The relative protein levels estimated from [20], [21], and the consensus
dataset were correlated to mRNA levels from [30] (a) or to mRNA levels from [29] (b). The
correlations are shown as a function of the median correlation between protein estimates
from [20] and [21]. The consensus dataset exhibits the highest correlations, suggesting that it has
averaged out some of the noise in each dataset and provides a more reliable quantification of of
human tissue proteomes. (c) The datasets from [20], from [21], and the consensus dataset were
evaluated by comparison to a targeted MS validation dataset quantifying 33 proteins over 5
tissues [22]. The similarity for each dataset was quantified by the mean squared error (MSE)
relative to the targeted MS validation data using 124 protein/tissue measurements that were
observed in all datasets. The MSEs are reported for each of the five tissues and for all 5 tissues
combined; they indicate that the consensus data have the best agreement with the validation
dataset.
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Supplemental Tables and Figures
Table S1. Estimates of relative protein-to-RNA (rPTR) ratio for GO terms reproduce
across different datasets Pearson correlations between two estimates of the median rPTR ratios
for all GO terms indicate reproducible effects in all tissues. As in Fig 2, rPTR estimates are
derived using independent data sources. The lower and upper estimates are the endpoints of the
95% confidence interval.
Table S2. Estimates of relative protein-to-RNA (rPTR) ratio for genes reproduce across
different datasets Correlations between the two estimates of rPTR ratios for all genes indicate
reproducible effects in all tissues. The rPTR ratios were estimated independently from different
datasets (as in Fig 2). The lower and upper estimates are the endpoints of the 95% confidence
interval.
Dataset S1. Consensus dataset of protein levels across human tissues A zip-archived comma-
delimited text file with consensus estimates of protein levels across 13 human tissues: adrenal
gland, colon, esophagus, kidney, liver, lung, ovary, pancreas, prostate, testis, spleen, stomach, and
heart.
Dataset S2. Peptide levels across human tissues A zip-archived comma-delimited text file with
estimates of peptide levels across 13 human tissues: adrenal gland, colon, esophagus, kidney,
liver, lung, ovary, pancreas, prostate, testis, spleen, stomach, and heart. This file contains all
peptide levels (integrated precursors areas) estimated from the MaxQuant searches described in
the Methods.
Figure S1. The total protein variance explained by scaled mRNA levels is not indicative of
the correlations between mRNA and protein fold-changes across the corresponding tissue
pairs. (a-c, top row), protein versus mRNA in kidney, liver and prostate. (d-f, middle row) protein
versus scaled mRNA in kidney, liver and prostate. The only difference from the top row is that the
mRNA was scaled by the median PTR. (g-i, bottom row) protein fold changes versus the
corresponding mRNA fold changes between the tissues indicated on the top. While scaled mRNA
is predictive of the absolute protein levels the accuracy of these predictions does not generally
reflect the accuracy of protein fold-changes across tissues that are predicted from the
corresponding mRNA fold-changes. RNA fold changes in (g-i, bottom row) were computed
between the mRNA levels without PTR scaling.
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Figure S2. Fraction of across-tissues variability in protein levels explained by RNA
variability for different functional gene sets. (a) The distributions of across-tissues correlations
for gene sets defined by the gene ontology are shown as boxplots. The reliability of RNA and
protein are estimated as the correlations between estimates from different datasets. (b) For each
gene set, the median RNA-protein correlation was corrected by the median reliabilities and the
results shown as a boxplot. Differences between RNA-protein correlations for different gene-sets
cannot be explained simply by differences in the reliabilities.
Figure S3. Reproducibility of rPTR ratios estimated from different datasets The x-axes
shows estimates from Wilhelm et al. [20] and the y-axes estimates from Kim et al. [21].
